Initiation of Tumor Necrosis Factor-α Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune Diseases
Top Cited Papers
Open Access
- 7 December 2011
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 306 (21) , 2331-2339
- https://doi.org/10.1001/jama.2011.1692
Abstract
Although the introduction of tumor necrosis factor (TNF)-α antagonists revolutionized the treatment of autoimmune diseases, concerns about the safety of these biologic drugs remain.1,2 Several studies reported serious infections in users of TNF-α antagonists.1-3 However, whether the risk of serious infections with TNF-α antagonists is greater than that with comparator nonbiologic medications is unclear.Keywords
This publication has 51 references indexed in Scilit:
- Study design for a comprehensive assessment of biologic safety using multiple healthcare data systemsPharmacoepidemiology and Drug Safety, 2011
- TNF-α Antagonist Use and Risk of Hospitalization for Infection in a National Cohort of Veterans With Rheumatoid ArthritisMedicine, 2011
- Receipt of Disease-Modifying Antirheumatic Drugs Among Patients With Rheumatoid Arthritis in Medicare Managed Care PlansJAMA, 2011
- Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderlyRheumatology, 2010
- Privacy-Maintaining Propensity Score-Based Pooling of Multiple Databases Applied to a Study of BiologicsMedical Care, 2010
- Initiation of rheumatoid arthritis treatments and the risk of serious infectionsRheumatology, 2009
- Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patientsJournal of Clinical Epidemiology, 2009
- Drug‐specific and time‐dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor α antagonistsArthritis & Rheumatism, 2007
- Serious infection following anti–tumor necrosis factor α therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studiesArthritis & Rheumatism, 2007
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006